Compare Ascendis Pharma A/S (ASND) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Huntington Bancshares Incorporated — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Huntington Bancshares Incorporated trades at $17.93 (market cap $36.22B). The key difference: Huntington Bancshares Incorporated is far larger — about 2× Ascendis Pharma A/S's market cap, and Huntington Bancshares Incorporated pays a 3.47% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HBAN | |
|---|---|---|
Market Cap | $17.74B | $36.22B |
Sector | Health | Financials |
52-Week High | $277.18 | $19.27 |
52-Week Low | $163.32 | $15.02 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HBAN trades at $17.87, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.25. Recent Q1 2026 earnings beat expectations with EPS of $0.26, and revenue for 2025 grew to $8.13B. The company maintains a solid net income margin of 25.13% and a P/E ratio of 13.75, indicating reasonable valuation. News highlights include expansion in Texas and a recent dividend payment, supporting positive sentiment.
The outlook for HBAN is positive, with growth driven by strategic acquisitions and organic loan expansion, though risks include integration challenges and competitive pressures in regional banking. Analysts are predominantly bullish, with 49% recommending buy, suggesting potential upside from current levels if earnings targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
